Science Journal Classics: Progress In BBB Experimental Research

Nucleic Acid Based Therapies, Such As Small Interfering RNA (siRNA), May Help To Treat Diseases That Are Considered "untreatable" By Small Molecule Drugs. The Identification Of Important Genes In Some Neurodegenerative Diseases Shows The Prospect Of This Research Field, But It Is Still A Challenge For SiRNA To Pass Through The Blood Brain Barrier (BBB) And Enter The Brain. Now, A Kind Of Nanoparticles Has Been Developed To Promote The Transmission In Mice. In Fact, In A Mouse Model Of Traumatic Brain Injury (TBI), The Accumulation Of This Transmission System In The Brain Is Three Times That Of Traditional Methods. This Work Shows That This Nano Particle Platform May Be A Promising New Generation Of Drug Delivery Method For Treating TBI. This Research Was Published In The Journal Of Scientific Progress, And The Title Was "BBB Pathophysiology - Independent Transmission Of SiRNA In Traumatic Brain Injury", Medical Professor Of Brigham Women's Hospital Of Harvard Medical School Dr. Jeff Kapp, The Joint Senior Author, Said: "It Is A Holy Grail In This Field To Be Able To Deliver Drugs To The Whole BBB Without Inflammation." Our Method Is Very Simple, And Is Applicable To The Treatment Of Many Nervous System Diseases That Need To Deliver Therapeutic Drugs To The Brain. "Traumatic Brain Injury Is The Main Cause Of Death And Disability Of Children And Adolescents. Millions Of People Are Involved In Accidents Traumatic Brain Injury In Sports And Military Conflicts. TBI Not Only Leads To Potential Long-term Neurological Dysfunction, Memory Impairment, Behavioral Changes, Speech Irregularities And Gait Abnormalities, But Also Is Related To The Development Of Neurodegenerative Diseases, Especially Chronic Traumatic Encephalopathy, Alzheimer's Disease, Parkinson's Disease, Etc& Nbsp; The Previously Developed Method Of Delivering Therapeutic Drugs To The Brain After Brain Injury Depends On The Short Time Window After Head Physical Injury, When The Blood Brain Barrier Is Temporarily Destroyed. However, After BBB Was Repaired Within A Few Weeks, Doctors Began To Lack Effective Drug Delivery Tools. Dr. Nitin Joshi, The Author Of The Correspondence, Said: "It Is Very Difficult To Deliver Small And Large Molecular Therapeutic Drugs Through The Blood-brain Barrier." Dr. Nitin Joshi Is A Bioengineer Of The Brigham Department Of Anesthesia, Perioperative And Pain Medicine Nanomedicine Center. "Our Solution Is To Encapsulate Therapeutic Drugs Into Biocompatible Nanoparticles. The Precisely Designed Surface Characteristics Of These Nanoparticles Enable Them To Be Effectively Transported To The Brain Without Relying On The Blood Brain Barrier." The SiRNA Molecule In This Study Aims To Inhibit The Expression Of Tau Protein, Which Is Considered To Play A Key Role In Neurodegenerative Change. Polylactic Acid Hydroxyacetic Acid (PLGA) Is A Biodegradable And Biocompatible Polymer, Which Is Used In Several Existing FDA Approved Products And As The Base Material Of Nanoparticles. The Researchers Designed A Unique Nanoparticle Design To Maximize The Transport Of Encapsulated SiRNA Through The Complete Blood-brain Barrier And Significantly Improve The Uptake Of Brain Cells. " This Report Not Only Shows The Mechanism Of Drug Delivery To The Brain, But Also Determines For The First Time That The Modulation Of The System Can Use Surface Chemistry And Coating Density To Adjust The Tight Connection Of The Nanoparticle's Permeable Biological Barrier, "said The First Author. In TBI Mice Receiving Anti Tau SiRNA Through The New Delivery System, A 50% Reduction In Tau Protein Expression Was Observed, Whether The Formulation Was Injected In A Temporary Window That Broke The Blood-brain Barrier Or Externally. In Contrast, The Tau Protein Of Mice Receiving SiRNA Through Their Own System Was Not Affected. The Second Author Further Emphasized That BBB Can Treat A Wide Range Of Acute And Chronic Diseases Of The Central Nervous System (CNS) With Drugs. She Said: "The Technology Developed This Time Can Be Used For A Large Number Of Different Drugs, Including Antibiotics, Anti-tumor Drugs And Neuropeptides." "This May Change The Rules Of The Game For Many Diseases Manifested In The Central Nervous System."; In Addition To Targeting Tau Protein, Researchers Are Also Studying How To Use The New Transmission Platform To Attack Other Targets. Karp Said: "In Terms Of Clinical Transformation, We Hope To Go Beyond Tau Protein To Verify Whether Our System Is Applicable To Other Targets." "We Use Traumatic Brain Injury Models To Explore And Develop This Technology, But Basically Anyone Who Studies Neurological Disorders May Find The Benefits Of This Work. Of Course, We Have A Lot Of Work To Do, But I Think It Provides An Important Impetus For Us To Move Towards A Variety Of Therapeutic Targets."   Some Classical References Of Cell Systems Primary Cell BBB Experiment: 1& Nbsp; Brown JA, Pensabene V, Markov DA, Allwardt V, Neely MD, Shi M, Britt CM, Hoilett OS, Yang Q, Brewer BM, Samson PC, McCawley LJ, May JM, Webb DJ, Li D, Bowman AB, Reiserer RS, Wikswo JP. Biomicrofluidics.& Nbsp; 2015 Sep;& Nbsp; 9(5): 054124.  Doi: 10.1063/1.4934713  Herland A, Van Der Meer AD, FitzGerald EA, Park T-E, Sleeboom JJF, Ingber DE. PLoS ONE. 2016; 11(3): E0150360. Doi: 10.1371/journal.pone.0150360 & Nbsp;